Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents

Table 2

Demographic characteristics and clinical history among patients with HER2-targeted agents.

	Patients with HER2-targeted agents
	HT−	HT+	De novo	Recurrent	Age 18–44	Age 45–64	Age 65+
All patients—
Age, mean (SD)	55.7 (10.8)	55.4 (11.6)	55.2 (11.4)	55.7 (11.2)	38.6 (4.3)	55.1 (5.5)	73.6 (6.3)^a
Urban	83.3%	83.9%	82.9%	84.1%	87.6%	82.8%	83.3%
Payer
Commercial	84.3%	82.7%	84.3%	83.0%	100%	99.3%	0.5%
Medicare	15.7%	17.3%	15.7%	17.0%	0%	0.7%	99.5%
Insurance plan type^d							a
Comprehensive	10.3%	8.8%	9.0%	9.9%	1.7%	4.1%	40.1%
EPO or PPO	56.5%	57.6%	58.6%	56.2%	56.9%	60.6%	42.0%
POS	8.5%	9.6%	8.6%	9.3%	11.4%	10.0%	2.8%
HMO	15.2%	15.3%	13.9%	16.1%	19.3%	14.7%	13.7%
CDHP or HDHP	4.3%	3.8%	4.3%	3.9%	6.2%	4.5%	0.0%
Unknown	5.2%	4.9%	5.6%	4.7%	4.5%	6.1%	1.4%
Earlier stage breast cancer diagnosis	73.1%	72.3%	26.5%	99.9%^a	70.1%	72.6%	75.5%
Surgery for breast cancer^e	27.7%	24.3%	41.9%	23.5%^a	33.9%	25.5%	20.9%^b
Adjuvant/neoadjuvant treatment^f	75.2%	78.6%	39.8%	87.1%^a	77.1%	77.8%	71.6%
Radiation therapy^e	18.6%	17.2%	6.6%	19.7%^a	24.4%	17.6%	13.4%^c
Any antineoplastic treatment^e	70.9%	87.5%^a	49.2%	84.1%^a	85.9%	78.8%	75.9%^b
Hormone therapy	0.0%	66.1%^a	14.0%	37.0%^a	39.6%	31.5%	38.8%^b
Chemotherapy	50.0%	39.3%^a	36.0%	45.9%^b	47.0%	45.6%	38.1%^c
Non-HER2 biologic/HER2-targeted agents	67.4%	59.2%^a	34.1%	67.8%^a	67.1%	64.2%	55.6%^b
HER2-targeted agents	66.7%	58.4%^b	33.7%	66.9%^a	66.8%	63.4%	54.7%^b
Charlson Comorbidity Index (CCI), mean (SD)	4.05 (2.84)	3.71 (2.65)^b	4.38 (2.99)	3.62 (2.58)^a	3.88 (2.75)	3.83 (2.75)	4.03 (2.74)
NCCI mean (SD)	1.47 (0.93)	1.44 (0.85)	1.35 (0.76)	1.50 (0.76)^a	1.28 (0.66)	1.37 (0.77)	1.69 (1.12)^a
Comorbidities
Anemia	14.4%	13.6%	7.4%	17.9%	11.9%	13.9%	16.5%
Anxiety/depression	9.4%	8.0%	8.5%	8.8%	12.9%	8.3%	6.4%^b
Cardiac arrhythmia	6.4%	6.6%	7.2%	6.2%	3.5%	5.1%	15.8%^a
Cerebrovascular disease	2.5%	2.1%	2.5%	2.2%	0.5%	1.8%	6.1%^a
Congestive heart failure	3.8%	2.4%^c	1.3%	4.1%^a	0.7%	2.9%	5.9%^a
Coronary artery disease	4.3%	6.0%	4.7%	5.4%	1.0%	4.3%	12.7%^a
Chronic obstructive pulmonary disorder	3.9%	2.5%^c	3.4%	3.0%	0.5%	2.9%	6.8%^a
Diabetes	12.4%	10.5%	10.8%	11.9%	4.0%	10.4%	22.9%^a
Hypertension	28.7%	29.6%^b	28.3%	29.7%	7.4%	28.0%	55.0%^a
Number of metastasis sites at index, mean (SD)	1.67 (0.94)	1.57 (0.82)^b	1.85 (0.95)	1.48 (0.81)^a	1.55 (0.83)	1.65 (0.91)	1.51 (0.79)^b
Site of metastasis at index
Liver	20.2%	14.4%^a	17.9%	16.8%	14.1%	18.0%	17.0%
Lung	16.4%	10.9%^a	9.8%	15.7%^a	12.1%	13.4%	15.3%
Bone	29.8%	42.2%^a	35.7%	36.5%	36.6%	35.6%	38.2%
Brain	16.8%	11.4%^a	8.0%	17.6%^a	12.9%	14.2%	14.4%

= number of patients meeting study selection criteria.
value compared to corresponding HER2-targeted agent subgroup(s) <0.0001.
value compared to corresponding HER2-targeted agent subgroup(s) <0.01.
value compared to corresponding HER2-targeted agent subgroup(s) <0.05.
^dEPO: exclusive provider organizations, PPO: preferred provider organization plans, POS: point-of-service, HMO: health maintenance organization, CDHP: consumer-driven health plan, and HDHP: high deductible health plan.
^eThe denominator for the percentages is the number of patients with a diagnosis of an earlier stage breast cancer.
^fPercent of patients with surgery in the preindex period.